APA (7th ed.) Citation

GP, C., J, F., A, B., A, P., M, B., JM, L., . . . PB, C. (2019). Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(4), 1174. https://doi.org/10.1158/1078-0432.CCR-18-1047

Chicago Style (17th ed.) Citation

GP, Coffey, et al. "Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25, no. 4 (2019): 1174. https://doi.org/10.1158/1078-0432.CCR-18-1047.

MLA (9th ed.) Citation

GP, Coffey, et al. "Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 25, no. 4, 2019, p. 1174, https://doi.org/10.1158/1078-0432.CCR-18-1047.